GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Longevity Health Holdings Inc (NAS:XAGE) » Definitions » Debt-to-Equity

XAGE (Longevity Health Holdings) Debt-to-Equity : -0.14 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Longevity Health Holdings Debt-to-Equity?

Longevity Health Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.33 Mil. Longevity Health Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.31 Mil. Longevity Health Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-4.71 Mil. Longevity Health Holdings's debt to equity for the quarter that ended in Dec. 2024 was -0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Longevity Health Holdings's Debt-to-Equity or its related term are showing as below:

XAGE' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.33   Med: -0.12   Max: 0.09
Current: -0.14

During the past 4 years, the highest Debt-to-Equity Ratio of Longevity Health Holdings was 0.09. The lowest was -0.33. And the median was -0.12.

XAGE's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.38 vs XAGE: -0.14

Longevity Health Holdings Debt-to-Equity Historical Data

The historical data trend for Longevity Health Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Health Holdings Debt-to-Equity Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
-0.33 -0.10 0.09 -0.14

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -1.11 -0.58 -0.19 -0.14

Competitive Comparison of Longevity Health Holdings's Debt-to-Equity

For the Household & Personal Products subindustry, Longevity Health Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Health Holdings's Debt-to-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Longevity Health Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Longevity Health Holdings's Debt-to-Equity falls into.


;
;

Longevity Health Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Longevity Health Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Longevity Health Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longevity Health Holdings  (NAS:XAGE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Longevity Health Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Longevity Health Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Health Holdings Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a United States based bio-aesthetics company that utilizes the Secretome to support skin and hair health.
Executives
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036